TrialInternational journal of hematology2013

Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.

Yasushi Takamatsu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.